KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Receivables (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Change in Receivables for 13 consecutive years, with $559000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 2.19% to $559000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$104000.0 through Dec 2025, down 116.94% year-over-year, with the annual reading at -$104000.0 for FY2025, 116.94% down from the prior year.
  • Change in Receivables for Q4 2025 was $559000.0 at Xenon Pharmaceuticals, up from -$283000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $7.2 million in Q1 2025, with the low at -$7.6 million in Q2 2025.
  • Average Change in Receivables over 5 years is -$45900.0, with a median of -$22500.0 recorded in 2022.
  • Peak annual rise in Change in Receivables hit 18989.47% in 2025, while the deepest fall reached 34454.55% in 2025.
  • Over 5 years, Change in Receivables stood at -$481000.0 in 2021, then tumbled by 214.97% to -$1.5 million in 2022, then skyrocketed by 119.41% to $294000.0 in 2023, then soared by 86.05% to $547000.0 in 2024, then increased by 2.19% to $559000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $559000.0, -$283000.0, and -$7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.